KEYNOTE-006: Long-term Outcomes After Pembrolizumab for Advanced Melanoma

June 2-6, 2017; Chicago, Illinois
A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 491 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings